公开(公告)号：US20250109136A1

公开(公告)日：2025-04-03

申请号：US18793023

申请日：2024-08-02

Applicant: Genentech, Inc.

Inventor： Chen MAO ,  Dawen KOU ,  Po-Chang CHIANG

IPC: C07D487/04 ,  A61K9/10 ,  A61K9/14 ,  A61K9/20 ,  A61K31/4985 ,  C07C309/04

Abstract: The invention relates generally crystalline mesylate salts, crystalline chloride salts and crystalline sulfate salts of the compound(S)-2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino) -6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one that is an inhibitor of Bruton's tyrosine kinase. In some aspects, the crystalline salts are single polymorphs.

公开(公告)号：US20250087299A1

公开(公告)日：2025-03-13

申请号：US18960282

申请日：2024-11-26

Applicant: Genentech, Inc.

Inventor： Benjamin Thomas WALTERS

IPC: G16B15/30

Abstract: In one aspect, a method for identifying residues in a particular conformation of a protein molecule capable of forming a stable binding between a compound and the protein molecule is provided. The method can include identifying, for inclusion in a perturbation set, one or more residues from the conformation of the protein molecule that exhibit a protection factor satisfying one or more thresholds. One or more residues may be excluded from the perturbation set based at least on a spatial arrangement and/or an orientation of the one or more residues. One or more rounds of molecular dynamics simulations whose result is indicative of an interaction between the compound and the residues in the perturbation set may be performed. The residues in the perturbation set may be identified as forming a stable binding between the compound and the protein molecule based at least on the result of the molecular dynamics simulation

公开(公告)号：US20250073345A1

公开(公告)日：2025-03-06

申请号：US18784398

申请日：2024-07-25

Applicant: Genentech, Inc.

Inventor： Daniel P. SUTHERLIN ,  Donglu ZHANG ,  Summer A. BAKER DOCKERY ,  Peter Scott DRAGOVICH

IPC: A61K47/68

Abstract: The subject matter described herein is directed to molecules referred to herein as chemical inducers of degradation (CIDEs) and antibody-conjugated CIDEs (Ab-CIDEs), wherein the Ab-CIDEs comprise an antibody covalently bound to the CIDE through a linker, wherein the CIDE can be further covalently bound to a phosphate moiety, and to the uses of the molecules in treating diseases and conditions where targeted protein degradation is beneficial.

公开(公告)号：US12239817B2

公开(公告)日：2025-03-04

申请号：US17795506

申请日：2021-01-26

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Kai Zheng ,  Edward Porock ,  Mahesh Khurana ,  Geoffrey Colin Wise ,  Lorenzo Myles Paredes Pesino ,  Michelle Hatch ,  Stefan Yohe ,  Raffaella Claudia Bondi

IPC: A61M5/14 ,  A61J1/14 ,  A61M5/142 ,  B65D23/00

Abstract: An apparatus and method for direct drug infusion from a vial to a patient are provided. A movable hanger label is provided to adhere to and support the vial to facilitate direct infusion of a drug, such as one or more pharmaceuticals, biopharmaceuticals, and/or biologics, from the vial to the patient. Additionally, a process is provided in which the drug, contained in the vial with the movable hanger label, may be directly infused through a primed infusion line with a rapid infusion rate. A saline flush is incorporated at the end of the administration to flush the infusion line, resulting in a reduced amount of the drug remaining in the line.

公开(公告)号：US20250061965A1

公开(公告)日：2025-02-20

申请号：US18941251

申请日：2024-11-08

Applicant: Genentech, Inc.

Inventor： Zia KHAN ,  Matthew Lawrence ALBERT ,  G Scott CHANDLER

IPC: G16B20/20 ,  G16B30/00 ,  G16H10/40 ,  G16H20/40 ,  G16H50/30

Abstract: Provided herein are diagnostic and therapeutic methods for the treatment of cancer using polygenic risk scores (PRSs) for dermatological autoimmune diseases. In particular, the invention provides methods for patient selection and methods of treatment.

公开(公告)号：US12215143B2

公开(公告)日：2025-02-04

申请号：US17576344

申请日：2022-01-14

Applicant: Genentech, Inc.

Inventor： Vishva Dixit ,  Marissa Matsumoto ,  Erick Castellanos

IPC: C07K16/18 ,  C12N15/62 ,  G01N33/68

Abstract: The invention provides antibodies that bind mixed-topology polyubiquitin and multispecific anti-polyubiquitin antibodies, and methods of using the same.

公开(公告)号：US20250034280A1

公开(公告)日：2025-01-30

申请号：US18743859

申请日：2024-06-14

Applicant: Novartis AG ,  Genentech, Inc.

Inventor： Maria Chaikou ,  Mathieu Paul- Léon Rigollet

IPC: C07K16/42 ,  A61K9/00 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61M5/315

Abstract: A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg/mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

公开(公告)号：US12205386B2

公开(公告)日：2025-01-21

申请号：US17841610

申请日：2022-06-15

Applicant: Genentech, Inc.

Inventor： Zheng Li ,  Mandy Man Chu Yim ,  Bibi Ephraim ,  Dat Tran ,  Xinyu Liu ,  David Shaw

IPC: G06V20/69 ,  G06T7/00 ,  G06T7/11 ,  G06T7/73 ,  G06V10/25 ,  G06V10/44 ,  G06V10/82

Abstract: A method includes, by a computing system, receiving a querying image depicting a sampling area, processing the querying image using a single cluster detection model to identify one or more regions of the querying image depicting a cluster in the sampling area, processing the one or more regions using a cluster verification deep-learning model to determine whether each depicted cluster is a cell cluster, and determining that exactly one of the identified one or more regions depicts a cluster that is a cell cluster. The method further includes processing the region depicting the cell cluster using a morphology deep-learning model to determine that there is only one cell in the cell cluster and to determine that die morphology of the cell is acceptable.

公开(公告)号：US20250019364A1

公开(公告)日：2025-01-16

申请号：US18883472

申请日：2024-09-12

Applicant: AbbVie Inc. ,  Genentech, Inc. ,  The Walter and Eliza Hall Institute of Medical Research

Inventor： Milan Bruncko ,  Hong Ding ,  George A. Doherty ,  Steven W. Elmore ,  Lisa A. Hasvold ,  Laura Hexamer ,  Aaron R. Kunzer ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao ,  Gary T. Wang ,  Le Wang ,  Xilu Wang ,  Michael D. Wendt ,  Robert Mantei ,  Todd M. Hansen

IPC: C07D401/12 ,  A61K31/496 ,  C07D209/82 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04 ,  C07D519/00

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

公开(公告)号：US20250018032A1

公开(公告)日：2025-01-16

申请号：US18893603

申请日：2024-09-23

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Mark C. Benyunes ,  Graham Alexander Ross

IPC: A61K39/395 ,  A61K9/00 ,  A61K31/337 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/32

Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.